Trevi Therapeutics shifts to late-stage biotech with Haduvio for IPF chronic cough. Click here to read my latest analysis of ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.

In what shakes out to be the largest follow-on stock offering in biopharma history, Revolution Medicines Inc., an oncology company that was the subject of buyout rumors earlier this year, priced 10.56 ...

Peer-reviewed study confirming strong predictive performance of patient-specific lung digital twins, validated against ...

A protein called PIEZO1, which is linked to mechanical stress, may play a key role in driving pulmonary fibrosis, a study ...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies ...

Cautionary Language Concerning Forward-Looking Statements ...

Ebenbuild GmbH, a Munich-based deep-tech healthcare company, today announced the publication of a peer-reviewed ...

Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told BioWorld. Remedy is taking a secretome-based approach to treat ...

Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.